
Issuing stock
Epstein Engineering Inc. began operations on January 5, 20Y8, with the issuance of 500,000shares of $80 par common stock. The sole stockholders of Epstein Engineering Inc. are Barb Abrams and Dr. Amber Epstein, who organized Epstein Engineering Inc. with the objective of developing a new flu vaccine. Dr. Epstein claims that the flu vaccine, which is nearing the final development stage, will protect individuals against 90% of the flu types that have been medically identified. To complete the project, Epstein Engineering Inc. needs $25,000,000 of additional funds. The local banks have been unwilling to loan the funds because of the lack of sufficient collateral and the riskiness of the business.
The following is a conversation between Barb Abrams, the chief executive officer of Epstein Engineering Inc., and Amber Epstein, the leading researcher:
Barb: What are we going to do? The banks won’t loan us any more money, and we’ve got to have $25 million to complete the project. We are so close! It would be a disaster to quit now. The only thing I can think of is to issue additional stock. Do you have any suggestions?
Amber: I guess you’re right. But if the banks won’t loan us any more money, how can we find any investors to buy stock?
Barb: I’ve been thinking about that. What if we promise the investors that we will pay them 5% of sales until they receive an amount equal to what they paid for the stock?
Amber: What happens when we pay back the $25 million? Do the investors get to keep the stock? If they do, it’ll dilute our ownership.
Barb: How about if after we pay back the $25 million, we make them turn in their stock for $120 per share? That’s one and one-half times what they paid for it, and they would have already gotten all their money back. That’s a $120 profit per share for the investors.
Amber: It could work. We get our money but don’t have to pay any interest, dividends, or the $80 per share until we start generating sales. At the same time, the investors could get their money back plus $120 per share profit.
Barb: We’ll need current financial statements for the new investors. I’ll get our accountant working on them and contact our attorney to draw up a legally binding contract for the new investors. Yes, this could work.
In late 20Y8, the attorney and the various regulatory authorities approved the new stock offering, and 312,500 shares of common stock were privately sold to new investors at the stock’s par of $80.
In preparing financial statements for 20Y8, Barb Abrams and Dan Fisher, the controller for Epstein Engineering Inc., have the following conversation:
Dan: Barb, I’ve got a problem.
Barb: What’s that, Dan?
Dan: Issuing common stock to raise that additional $25 million was a great idea. But . . .
Barb: But what?
Dan: I’ve got to prepare the 20Y8 annual financial statements, and I am not sure how to classify the common stock.
Barb: What do you mean? It’s common stock.
Dan: I’m not so sure. I called the auditor and explained how we are contractually obligated to pay the new stockholders5% of sales until $80 per share is paid. Then we may be obligated to pay them $120 per share.
Barb: So . . .
Dan: So the auditor thinks that we should classify the additional issuance of $25 million as debt, not stock! And if we put the $25 million on the
- 1.
Discuss the arguments for and against classifying the issuance of the $25 million of stock as debt.
- 2.
What might be a practical solution to this classification problem?

Want to see the full answer?
Check out a sample textbook solution
Chapter 13 Solutions
Financial Accounting
- Please solve this General accounting questions step by steparrow_forwardWhat is the ending inventory?arrow_forwardExercise 10-8 (Algo) Prepare the stockholders' equity section (LO10-7) The Golden Mushroom has two classes of stock authorized 8%, $10 par preferred, and $1 par value common. The following transactions affect stockholders' equity during 2024, its first year of operations January 2 February 6 Issues 100,000 shares of common stock for $28 per share. Issues 2,300 shares of a preferred stock for $12 per share. September 10 Purchases 10,000 shares of its own common stock for $33 per share. December 15 Resells 5,000 shares of treasury stock at $38 per share. In its first year of operations. The Golden Mushroom has net income of $153,000 and pays dividends at the end of the year of $95,000 ($1 per share) on all common shares outstanding and $1,840 on all preferred shares outstanding Required: Prepare the stockholders' equity section of the balance sheet for The Golden Mushroom as of December 31, 2024. (Amounts to be deducted should be indicated by a minus sign) THE GOLDEN MUSHROOM Balance…arrow_forward
- Financial AccountingAccountingISBN:9781305088436Author:Carl Warren, Jim Reeve, Jonathan DuchacPublisher:Cengage LearningFinancial AccountingAccountingISBN:9781337272124Author:Carl Warren, James M. Reeve, Jonathan DuchacPublisher:Cengage LearningSurvey of Accounting (Accounting I)AccountingISBN:9781305961883Author:Carl WarrenPublisher:Cengage Learning


